The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Ezmekly (mirdametinib) for the treatment of ...
An end-of-the-year slowdown has not been witnessed by the biopharma industry yet, and certainly not in the biotech deals ...
Europe's universities and research institutes are particularly strong in biotech and pharmaceutical startups. A report from Dealroom shows that since 2022 there have been 244 academic spinouts in ...
By Annette Bakker The tragedy of rare disease is not only measured in lives lost—it’s also measured in lives that could have ...
Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision ...
Merck & Co., Inc. (NYSE:MRK) is a global pharmaceutical company recognized for its strong oncology lineup, led by its flagship drug Keytruda, the top-selling medicine in the world. The ...
SpringWorks Therapeutics, a Merck company, announced that the European Commission has granted conditional marketing authorization for EZMEKLY® (mirdametinib) for the treatment of symptomatic, ...
Merck KGaA is still scouting for acquisition targets after the German drug-to-semiconductor group completed its $3.9 billion takeover of SpringWorks Therapeutics Inc. on Tuesday. “The SpringWorks ...
SpringWorks immediately adds revenue and accelerates mid- to long-term growth for Merck KGaA, Darmstadt, Germany’s Healthcare business sector. Acquisition marks the formation of a rare tumor business ...
Merck KGaA struck a $3.9 billion deal for SpringWorks Therapeutics. Novartis plans to acquire Regulus Therapeutics for $800 million upfront and up to $1.7 billion overall. Biohaven signed a $600 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback